Tenacia Biopharmaceuticals (Shanghai) Co., Ltd., a Bain Capital-incubated CNS specialist, announced a licensing agreement with Golden Age Health Pte. Ltd. (GAH), granting the Singapore-headquartered firm exclusive commercialization rights to Ztalmy (ganaxolone oral suspension) in mainland China. The neuroactive steroid, approved in China (July 2024) for CDKL5 deficiency disorder (CDD)-associated seizures, remains the first and only therapy for this rare epileptic encephalopathy affecting patients aged 2 years and older.
Transaction Overview
Element
Detail
Licensor
Tenacia Biopharmaceuticals (Shanghai) Co., Ltd. (Bain Capital portfolio)
Licensee
Golden Age Health Pte. Ltd. (GAH) – Singapore-headquartered
Asset
Ztalmy (ganaxolone oral suspension)
Territory
Mainland China (exclusive commercialization rights)
Original License
Tenacia licensed from Marinus Pharmaceuticals for Greater China
China Approval
July 2024 – first and only approved therapy for CDD-associated seizures
Target Population
Patients aged ≥2 years with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder
Disease Context & Unmet Need
Parameter
CDKL5 Deficiency Disorder (CDD) Profile
Genetic Basis
Mutations in CDKL5 gene on X chromosome
Clinical Presentation
Early-onset, refractory seizures; severe developmental delay; motor impairment
Epidemiology
Ultra-rare – estimated 1,000–2,000 diagnosed patients in China
Treatment Landscape
No approved therapies prior to Ztalmy; standard of care = multiple antiepileptic drugs with limited efficacy
Mechanism
Neuroactive steroid – positive allosteric modulator of GABA-A receptors; distinct from traditional AEDs
Strategic Rationale
Tenacia Bio Perspective
Golden Age Health Perspective
Commercial focus shift – partner with China distribution specialist while retaining development rights
Rare disease entry – exclusive rights to first-in-class asset in underserved market
Bain Capital portfolio optimization – monetize commercial rights; retain upside via milestones/royalties
Neurology expertise – GAH CNS commercial infrastructure aligns with Ztalmy patient identification needs
Patient access acceleration – leverage GAH relationships with pediatric neurology centers
Orphan drug economics – premium pricing (~RMB 200,000–300,000 annually) supports viable rare disease business model
First-mover advantage – 2–3 year competitive lead before potential generics or biosimilars
Market Context & Commercial Outlook
Factor
Implication
China Rare Disease Policy
National Rare Disease List (2018, 2023 expansions) supports reimbursement; CDD inclusion facilitates NRDL negotiation
Ztalmy Differentiation
First and only approved CDD therapy in China; neuroactive steroid mechanism offers seizure reduction + neurodevelopmental benefits
Patient Identification
Genetic testing expansion in pediatric epilepsy centers critical for diagnosis; GAH medical education investment required
Revenue Potential
Addressable market RMB 200–400 million annually (500–1,000 treated patients × RMB 200,000–400,000 price); GAH break-even by Year 3
Tenacia Retained Rights
Development and commercialization rights for other indications (e.g., tuberous sclerosis complex, Lennox-Gastaut syndrome)
Commercial Timeline: GAH sales force deployment Q2 2026; hospital listing in tertiary pediatric neurology centers prioritized
Regulatory Strategy: NRDL negotiation 2027 to expand reimbursement and patient access beyond private pay
Forward‑Looking Statements This brief contains forward‑looking statements regarding patient identification rates, reimbursement negotiations, and commercial execution for Ztalmy in mainland China. Actual results may differ due to genetic testing penetration, competitive entry from other neuroactive steroids, and rare disease policy implementation variability across provinces.-Fineline Info & Tech
By Fineline Cube